Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)
Clinical trial NCT02939014 · COMPLETED
Trial details
- NCT number
- NCT02939014
- Sponsor
- Takeda
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-07
- Primary completion
- 2018-08-02
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.